financial guidance
The company also said that its Diagnostics and Genomics revenues were down 1 percent during fiscal Q4, although its overall revenues were up slightly.
Twist Bioscience Fiscal Q4 Revenues Jump 27 Percent
The South San Francisco, California-based firm booked $84.7 million in revenues for fiscal Q4 revenues and $313.0 million for FY 2024, both record numbers for the company.
Akoya Biosciences Stock Slumps Following Disappointing Q3 Results
The spatial biology firm lowered its 2024 guidance for the third consecutive quarter and said it is considering strategic alternatives for its business.
Natera Q3 Revenues Grow 64 Percent
Strong product sales, mainly from oncology tests, drove the company's revenue growth, prompting it to raise its full year guidance.
Quanterix Counting on Multi-Marker Approach as Differentiator in Crowded Alzheimer's Dx Field
Premium
The company expects its five-marker LucentAD Complete test to offer higher performance than single-marker assay and to secure higher reimbursement.